Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
1 study
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin
- Obesity / overweight💵 May compensate
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Testing whether tirzepatide affects liver fat markers in people with obesity
📍 University of New Mexico Health Sciences Center · Albuquerque, NM · Get directions →
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity.